The IPC Virtual Psoriasis Masterclass is designed for early career dermatologists who are making treatment decisions and managing patients with psoriasis and are interested in specializing in psoriasis.
Over the five weekly two hours of the course, IPC’s world-renowned experts will cover various topics, including the pathogenesis of psoriasis, new and emerging therapies, and how to advocate for your patient.
The Masterclass agenda has been carefully developed to provide knowledge for daily use to the practicing dermatologist in an intimate environment designed to maximize faculty/participant interactions. Through lectures, panels, case-based discussions and question-answer sessions, attendees will obtain practical and important information for their clinical practice.
The IPC Masterclass is open to dermatologists who meet the following criteria:
There is no cost to attend the program, but space is limited. The application deadline is April 16, 2025.
Timezones:
15:00-17:00 BST
16:00-18:00 CEST
17:00-19:00 EEST
WELCOME + INTRODUCTION
Lone Skov, MD, PhD, Denmark
Epidemiology: The Size of the Problem
Juul van den Reek, MD, PhD, Netherlands
Genetic Determinants of Disease
Charlotta Enerbäck, MD, PhD, Sweden
Psoriasis Pathophysiology & Mechanisms
Curdin Conrad, MD, Switzerland
The Impact of Psoriasis
Matthias Augustin, MD, Germany
Understanding Patient Goals
Christine Bundy, PhD, AFBPS, C Psychol, United Kingdom
Q&A + CLOSING COMMENTS
Juul van den Reek, MD, PhD, Netherlands
WELCOME + INTRODUCTION
Juul van den Reek, MD, PhD, Netherlands
Clinical Phenotypes
Brian Kirby, MD, FRCPI, Ireland
Environmental Trigger Factors Including Koebner
Albert Duvetorp, MD, PhD, Sweden
What’s New in Pustular Psoriasis
Herve Bachelez, MD, PhD, France
Psoriasis in Children
Marieke Seyger, MD, PhD, Netherlands
Q&A + CLOSING COMMENTS
Paolo Gisondi, MD, Italy
WELCOME + INTRODUCTION
Paolo Gisondi, MD, Italy
Topicals: When and How to Use
Peter van de Kerkhof, MD, PhD, Netherlands
Phototherapy: Does it Still Have a Role?
Joel Gelfand, MD, MSCE, United States
Conventional Systemic Treatment and Small Molecules
Kasper Hjuler, MD, PhD, Denmark
Biologics: Where are We Now?
Paolo Gisondi, MD, Italy
Q&A + CLOSING COMMENTS
Lone Skov, MD, PhD, Denmark
WELCOME + INTRODUCTION
Lone Skov, MD, PhD, Denmark
Psoriasis Arthritis
Laura Coates, MBChB, PhD, United Kingdom
Psoriasis and Cardiovascular Diseases
Álvaro González-Cantero, MD, PhD, Spain
Psoriasis and Metabolic Disease Including Liver Disease
Lone Skov, MD, PhD, Denmark
Psoriasis, Infections and Cancer: What to Do
Caitriona Ryan, MD, Ireland
Q&A + CLOSING COMMENTS
Paolo Gisondi, MD, Italy
WELCOME + INTRODUCTION
Juul van den Reek, MD, PhD, Netherlands
Lifestyle & Diet: What We Know
Charlotte Näslund-Koch, MD, PhD, Denmark
Precision Medicine: What’s Coming Next
Catherine Smith, MD, United Kingdom
Hot Cases – Presented by Delegates
Faculty Panel
Q&A + CLOSING COMMENTS
All Chairs
A new IPC paper in JAAD presents five priorities for improving metabolic screening, advancing GLP-1 research in the context of psoriasis, and defining the dermatologist’s role in managing cardiometabolic risk in psoriasis patients.
IPC Jr. Councilor Mio Nakamura speaks with Dr. John Koo about how personality traits, including borderline personality disorder, shape clinical interactions and shares practical strategies for dermatologists to build stronger patient relationships.
Recordings from the IPC Fellows Research Class #1: Global and Collaborative Research in Psoriasis are now available. Program Chairs Peter van de Kerkhof, MD, PhD, and María Julia Cura, MD, led a faculty of international experts through sessions on unresolved questions in the era of effective psoriasis therapies, building global research collaborations, and connecting psoriasis research across disciplines. Watch to hear from Wolf Henning Boehncke, MD, MA, Christopher Griffiths, OBE, MD, FMedSci, and Georg Stingl, MD, as they share perspectives shaping the next generation of psoriasis research.
The IPC Resource Library now includes a dedicated Research Skills category, bringing together videos, articles, and presentations focused on building stronger research capabilities in psoriasis. Browse the current collection to find resources on topics from collaborative research methods to career development for researchers at every stage.
Rare ADAR1 gene mutations drive a distinct, interferon-fueled psoriasis subtype, and it responds to JAK1 and TYK2 inhibitors rather than standard IL-17/IL-23 biologics.
IPC Councilor Anna Lopez Ferrer, MD, PhD, reviews PURE-4, a four-item tool that helps dermatologists screen psoriasis patients for psoriatic arthritis (PsA) risk. She traces its evolution across three studies (2018–2026) into a validated predictor of early PsA.
IPC Councilor André Lucas Ribeiro, MD, reframes PsA as a slow transition from psoriasis, not a sudden event, opening the door to disease interception. He outlines the steps needed to get there, from harmonizing definitions to reducing inflammatory burden.
